Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Brain function and blood flow

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of two distinct pathways of human myelopoiesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A programmed wave of uridylation-primed mRNA degradation is essential for meiotic progression and mammalian spermatogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The key myeloid transcription factor (TF), CEBPA, is frequently mutated in acute myeloid leukemia (AML), but the direct molecular effects of this leukemic driver mutation remain elusive. To investigate CEBPA mutant AML, we performed microscale, in vivo chromatin immunoprecipitation sequencing and identified a set of aberrantly activated enhancers, exclusively occupied by the leukemia-associated CEBPA-p30 isoform. Comparing gene expression changes in human CEBPA mutant AML and the corresponding CebpaLp30 mouse model, we identified Nt5e, encoding CD73, as a cross-species AML gene with an upstream leukemic enhancer physically and functionally linked to the gene. Increased expression of CD73, mediated by the CEBPA-p30 isoform, sustained leukemic growth via the CD73/A2AR axis. Notably, targeting of this pathway enhanced survival of AML-transplanted mice. Our data thus indicate a first-in-class link between a cancer driver mutation in a TF and a druggable, direct transcriptional target.

Original languageEnglish
JournalScientific American
Volume5
Issue number7
Pages (from-to)eaaw4304
ISSN0036-8733
DOIs
Publication statusPublished - Jul 2019

ID: 57758371